Last reviewed · How we verify
HCP1102
HCP1102 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
HCP1102 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC).
At a glance
| Generic name | HCP1102 |
|---|---|
| Also known as | Singulair and Xyzal combination tablet |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Androgen receptor degrader (SARD) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HCP1102 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms seen with conventional anti-androgens.
Approved indications
- Castration-resistant prostate cancer (CRPC)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
Key clinical trials
- Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis (PHASE3)
- PK and Safety Study of HCP1102, HGP0813 and HGP1408 (PHASE1)
- Efficacy and Safety of HCP1102 Capsule (PHASE3)
- Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCP1102 CI brief — competitive landscape report
- HCP1102 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI